Briefly, WAT A4 primarily functions as an autocrine regulator of LPL during fasting by inhibiting LPL activity and promoting its degradation, and targeting A4 emerges as a promising therapeutic approach for managing dyslipidemia and cardiovascular diseases. Here, LPL is linked to metabolic syndrome.